Clinical applications of adipose-derived stromal vascular fraction in veterinary practice. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Sharun, Khan; Jambagi, Kaveri; Kumar, Rohit; Gugjoo, Mudasir Bashir; Pawde, Abhijit M.; Tuli, Hardeep Singh; Dhama, Kuldeep; Amarpal,
• Is Part Of: Veterinary quarterly. Volume 42:Issue 1(2022)
• Page Start: 151
• Page End: 166
• Publication Date: 2022-12-31
• Subjects: Mesenchymal stem cells -- stromal vascular fraction -- bone healing -- regenerative medicine -- enzymatic digestion -- adipose tissue -- veterinary medicine -- review; Veterinary medicine -- Periodicals; Veterinary Medicine; Veterinary medicine -- Periodicals; Veterinary research -- Periodicals; Veterinary medicine; Periodicals; Periodicals; 636.089
• DOI: 10.1080/01652176.2022.2102688
• Languages: English
• ISSNs: 0165-2176

Abstract

Abstract: Adipose tissue-derived stromal vascular fraction (AdSVF) comprises a heterogeneous cell population, including the multipotent mesenchymal stem cells, hematopoietic stem cells, immune cells, endothelial cells, fibroblasts, and pericytes. As such, multipotent adipose tissue-derived mesenchymal stem cells (AdMSCs), are one of the important components of AdSVF. Commonly used techniques to harvest AdSVF involve enzymatic or non-enzymatic methods. The enzymatic method is considered to be the gold standard technique due to its higher yield. The cellular components of AdSVF can be resuspended in normal saline, platelet-rich plasma, or phosphate-buffered saline to produce a ready-to-use solution. Freshly isolated AdSVF has exhibited promising osteogenic and vasculogenic capacity. AdSVF has already been proven to possess therapeutic potential for osteoarthritis management. It is also an attractive therapeutic option for enhancing wound healing. In addition, the combined use of AdSVF and platelet-rich plasma has an additive stimulatory effect in accelerating wound healing and can be considered an alternative to AdMSC treatment. It is also widely used for managing various orthopaedic conditions in clinical settings and has the potential for regenerating bone, cartilage, and tendons. Autologous AdSVF cells are used along with bone substitutes and other biological factors as an alternative to conventional bone grafting techniques owing to their promising osteogenic and vasculogenic capacity. It can also be used for treating osteonecrosis, meniscus tear, chondromalacia, and tendon injuries in veterinary practice. It has several advantages over in vitro expanded AdMSC, including precluding the need for culturing, reduced risk of cell contamination, and cost-effectiveness, making it ideal for clinical use.